Traws Pharma, Inc. (NASDAQ:TRAW) Stock Now Rated “Reduce” by Wall Street Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have been given an average rating of “Reduce” by the five brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $1.00.

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Traws Pharma in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th.

Traws Pharma Trading Down 6.6%

TRAW stock opened at $0.34 on Friday. The business’s fifty day moving average price is $0.51 and its 200 day moving average price is $0.89. Traws Pharma has a 12-month low of $0.33 and a 12-month high of $3.23. The company has a market capitalization of $5.26 million, a PE ratio of -0.20 and a beta of 1.52.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. Research analysts predict that Traws Pharma will post -1.20 EPS for the current fiscal year.

Traws Pharma Company Profile

Traws Pharma, Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing medicines for viral infections and cancer. The company’s research and development programs are focused primarily on oral antiviral therapies for respiratory viruses, including influenza and COVID-19.

Traws Pharma’s antiviral pipeline includes tivoxavir marboxil, an investigational treatment designed to inhibit viral replication in influenza A, along with additional antiviral candidates targeting respiratory infections.